Literature DB >> 30048112

Dendritic Cell-Targeted Nanovaccine Delivery System Prepared with an Immune-Active Polymer.

Mrigendra K S Rajput1,2, Siddharth S Kesharwani1, Sunny Kumar1, Pratik Muley1, Susmitha Narisetty1, Hemachand Tummala1.   

Abstract

Targeting dendritic cells (DCs), either ex vivo (Ex. Sipuleucel-T) or in vivo, for stimulating cellular immunity has been a leading approach for cancer vaccines. We have rationally engineered a nanoparticle (NP)-based delivery system for vaccines (InAc-NPs) using inulin acetate (InAc) as the polymer to target DCs. The material and the antigen-encapsulated InAc-NPs (∼190 nm in diameter) were characterized for their physicochemical properties. As a potent vaccine adjuvant, InAc-NPs activated TLR4 on multiple immune cells, including DCs and primary swine and human cells, to secrete various cytokines as detected by enzyme-linked immunosorbent assay and quantitative polymerase chain reaction. In addition, InAc-NPs promoted the maturation of DCs as observed by a decreased phagocytic ability and enhanced capability to activate various maturation markers (MHC-I, MHC-II, CD40, and CD80) quantified using flow cytometry. In mice, the InAc-NPs produced strong serum antibody titers (total IgG, IgG1, and IgG2a) against the encapsulated antigen (ovalbumin) similar to complete Freund's adjuvant. Additionally, as a dose-sparing delivery system, antigen delivered through InAc-NPs generated higher antibody titers (IgG1, 1.57 times; IgG-total, 1.66 times; and IgG2a, 29.8 times) even at 100 times less antigen dose. High amounts of cytokines representing both humoral (IL4 and IL10) and cell-mediated (IL2 and IFN-γ) immunities were secreted from splenocytes of mice immunized with InAc-NPs. Importantly, InAc-NPs provided complete protection in 100% of the vaccinated mice from metastasis of intravenously injected melanoma cells (B16-F10) to lungs. In addition, the InAc-NPs were cleared from the injection site within 30 h of injection (in vivo imaging) and displayed no toxicity at the injection site (histology). The current study demonstrates that the multifunctional InAc-based nanovaccine delivery system has potential applications in cancer immunotherapy and delivering vaccines against various infectious diseases.

Entities:  

Keywords:  cancer immunotherapy; dendritic cell targeting; humoral and cellular immunity; inulin acetate; nanoparticulate vaccine; toll-like receptor-4 agonists

Mesh:

Substances:

Year:  2018        PMID: 30048112     DOI: 10.1021/acsami.8b02019

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  11 in total

1.  Phenylboronic ester-modified polymeric nanoparticles for promoting TRP2 peptide antigen delivery in cancer immunotherapy.

Authors:  Qiyan Wang; Zhipeng Dong; Fangning Lou; Yunxue Yin; Jiahao Zhang; Hanning Wen; Tao Lu; Yue Wang
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

2.  A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model.

Authors:  Xin-Long Li; Shan Zeng; Hai-Ping He; Xu Zeng; Li-Lei Peng; Li-Gang Chen
Journal:  Onco Targets Ther       Date:  2020-08-14       Impact factor: 4.147

Review 3.  Polysaccharide-based nanomedicines for cancer immunotherapy: A review.

Authors:  Yujun Zeng; Yufan Xiang; Ruilong Sheng; Helena Tomás; João Rodrigues; Zhongwei Gu; Hu Zhang; Qiyong Gong; Kui Luo
Journal:  Bioact Mater       Date:  2021-03-18

4.  Combination Therapy of Lung Cancer Using Layer-by-Layer Cisplatin Prodrug and Curcumin Co-Encapsulated Nanomedicine.

Authors:  Yuan Hong; Shaomin Che; Beina Hui; Xiaoli Wang; Xiaozhi Zhang; Hailin Ma
Journal:  Drug Des Devel Ther       Date:  2020-06-09       Impact factor: 4.162

5.  Induction of Robust Immune Responses by CpG-ODN-Loaded Hollow Polymeric Nanoparticles for Antiviral and Vaccine Applications in Chickens.

Authors:  Shu-Yi Lin; Bing-Yu Yao; Che-Ming Jack Hu; Hui-Wen Chen
Journal:  Int J Nanomedicine       Date:  2020-05-11

Review 6.  Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics.

Authors:  Simon Van Herck; Bruno G De Geest
Journal:  Acta Pharmacol Sin       Date:  2020-05-25       Impact factor: 6.150

7.  Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy.

Authors:  Peiqi Zhao; Yuanlin Xu; Wei Ji; Lanfang Li; Lihua Qiu; Shiyong Zhou; Zhengzi Qian; Huilai Zhang
Journal:  Int J Nanomedicine       Date:  2022-01-07

8.  Injectable Nanoparticle-Based Hydrogels Enable the Safe and Effective Deployment of Immunostimulatory CD40 Agonist Antibodies.

Authors:  Santiago Correa; Emily L Meany; Emily C Gale; John H Klich; Olivia M Saouaf; Aaron T Mayer; Zunyu Xiao; Celine S Liong; Ryanne A Brown; Caitlin L Maikawa; Abigail K Grosskopf; Joseph L Mann; Juliana Idoyaga; Eric A Appel
Journal:  Adv Sci (Weinh)       Date:  2022-08-17       Impact factor: 17.521

Review 9.  Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what?

Authors:  Shiyi Zuo; Jiaxuan Song; Jingxuan Zhang; Zhonggui He; Bingjun Sun; Jin Sun
Journal:  Theranostics       Date:  2021-06-01       Impact factor: 11.556

Review 10.  Nanosystems Applied to HIV Infection: Prevention and Treatments.

Authors:  Micaela A Macchione; Dariana Aristizabal Bedoya; Francisco N Figueroa; María Ángeles Muñoz-Fernández; Miriam C Strumia
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.